Related Experiment Videos
Gene therapy for liver cirrhosis
1First Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan. sfujimo@hyo-med.ac.jp
Journal of Gastroenterology and Hepatology
|April 12, 2000
Summary
Hepatocyte growth factor (HGF) gene therapy shows promise for treating liver cirrhosis. In a rat model, HGF gene therapy reduced fibrosis and prevented cell death, suggesting potential for human treatment.
Area of Science:
- Hepatology
- Gene Therapy
- Regenerative Medicine
Background:
- Liver cirrhosis is irreversible scarring of the liver, a leading cause of global mortality.
- Current treatment strategies aim to prevent fibrosis, promote liver regeneration, and restore architecture.
- Chronic liver disease is driven by factors including viral infections and substance abuse.
Purpose of the Study:
- To investigate the efficacy of hepatocyte growth factor (HGF) gene therapy in a rat model of liver cirrhosis.
- To assess HGF gene therapy's impact on fibrogenesis, hepatocyte apoptosis, and liver architecture.
Main Methods:
- Induction of lethal liver cirrhosis in rats using dimethylnitrosamine.
- Repeated transfection of the HGF gene into skeletal muscle.
- Monitoring of plasma HGF levels and c-Met/HGF receptor phosphorylation.
Main Results:
- Achieved high plasma levels of HGF and activated the c-Met/HGF receptor pathway.
- Demonstrated inhibition of fibrogenesis and hepatocyte apoptosis.
- Observed resolution of liver fibrosis in cirrhotic rats.
Conclusions:
- HGF gene therapy effectively reversed liver fibrosis and protected hepatocytes in a cirrhotic rat model.
- This approach holds potential for treating liver cirrhosis in humans.
- Further research is warranted to explore clinical applications of HGF gene therapy for liver disease.